/ /

Michelle Dalton, ELS
Year in Review: Surgical Retina
Looking back at 2016, incremental improvements in devices are changing how retina surgeons approach and treat surgeries, said a group of experts. For Charles Wykoff, MD, PhD, two novel improvements may not radically alter surgical approaches today, but will have a long-lasting impact down the road.
Introducing 3-D OCT to live surgery
Introducing 3-D OCT to live surgery
The advent of three-dimensional optical coherence tomography to live surgery may bring greater clarity to how ophthalmologists visualize structures and how they operate.
Reverse side cut produces better self-sealing efficacy
A 110° reverse side cut primary incision created with a femtosecond laser provides an effective seal for potential wound leakage in a recent study.
Optimizing cataract outcomes when keratoconus is present
Optimizing cataract outcomes when keratoconus is present
Patients with keratoconus pose unique challenges with IOL calculations.
Improving IOL power calculations
An advanced, self-validating method is providing a new approach to IOL power selection, explains Warren E. Hill, MD, FACS.
Reducing pain during postop pediatric strabismus surgery
In a randomized study, patients receiving bupivocaine had lower pain scores than the control group in the first 30 minutes after surgery. However, other factors may also play a role.
Binkhorst Lecture: Predicting, treating keratoconus in 2016
The Binkhorst Lecture and Medal have been conferred since 1975 on “an individual whose career has made significant contributions to the science and practice of ophthalmology and established that person among the world’s most prominent ophthalmologists.”
Which is superior: LASIK or contact lenses?
Steven Dell, MD, and Steve Schallhorn, MD, compared the visual and subjective outcomes in patients who wear contact lenses with those who underwent wavefront-guided LASIK for the correction of myopia and astigmatism.
Treating all lenses equally
Intraocular lenses have come a long way in the 66 years since Harold Ridley first inserted one, said Alan Carlson, MD, professor of ophthalmology, Duke University, Durham, NC.
Rocket 2 meets safety endpoints for netarsudil
Netarsudil ophthalmic solution 0.02% q.d. maintained consistent IOP-lowering efficacy through 12 months for the Rocket 2 trial.

Poll

View Results